156 related articles for article (PubMed ID: 6540390)
1. Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation.
Spencer SE; Wooten GF
Neurology; 1984 Aug; 34(8):1105-8. PubMed ID: 6540390
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic effects of L-dopa are not closely linked temporally to striatal dopamine concentration.
Spencer SE; Wooten GF
Neurology; 1984 Dec; 34(12):1609-11. PubMed ID: 6504335
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action of L-dihydroxyphenylalanine in the "hemiparkinsonian" rat.
Orosz D; Bennett JP
Exp Neurol; 1992 Mar; 115(3):388-93. PubMed ID: 1537396
[TBL] [Abstract][Full Text] [Related]
4. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
6. Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms.
Robertson GS; Robertson HA
J Neurosci; 1989 Sep; 9(9):3326-31. PubMed ID: 2795165
[TBL] [Abstract][Full Text] [Related]
7. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
8. Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism.
Melamed E; Hefti F; Bitton V; Globus M
Neurology; 1984 Dec; 34(12):1566-70. PubMed ID: 6504328
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
[TBL] [Abstract][Full Text] [Related]
10. Decarboxylation of exogenous L-DOPA in rat striatum after lesions of the dopaminergic nigrostriatal neurons: the role of striatal capillaries.
Melamed E; Hefti F; Wurtman RJ
Brain Res; 1980 Sep; 198(1):244-8. PubMed ID: 7407592
[TBL] [Abstract][Full Text] [Related]
11. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.
Lee J; Zhu WM; Stanic D; Finkelstein DI; Horne MH; Henderson J; Lawrence AJ; O'Connor L; Tomas D; Drago J; Horne MK
Brain; 2008 Jun; 131(Pt 6):1574-87. PubMed ID: 18487277
[TBL] [Abstract][Full Text] [Related]
12. Chronic L-dopa administration decreases striatal accumulation of dopamine from exogenous L-dopa in rats with intact nigrostriatal projections.
Melamed E; Globus M; Friedlender E; Rosenthal J
Neurology; 1983 Jul; 33(7):950-3. PubMed ID: 6683384
[TBL] [Abstract][Full Text] [Related]
13. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
[TBL] [Abstract][Full Text] [Related]
14. 1-Benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous neurotoxic compound, disturbs the behavioral and biochemical effects of L-DOPA: in vivo and ex vivo studies in the rat.
Wąsik A; Romańska I; Michaluk J; Kajta M; Antkiewicz-Michaluk L
Neurotox Res; 2014 Oct; 26(3):240-54. PubMed ID: 24842650
[TBL] [Abstract][Full Text] [Related]
15. Evidence that the substantia nigra is a site of action for L-DOPA.
Robertson GS; Robertson HA
Neurosci Lett; 1988 Jun; 89(2):204-8. PubMed ID: 3393296
[TBL] [Abstract][Full Text] [Related]
16. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
17. Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease.
Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
Brain Res Rev; 2006 Sep; 52(2):244-56. PubMed ID: 16644019
[TBL] [Abstract][Full Text] [Related]
18. Endogenous melatonin protects L-DOPA from autoxidation in the striatal extracellular compartment of the freely moving rat: potential implication for long-term L-DOPA therapy in Parkinson's disease.
Rocchitta G; Migheli R; Esposito G; Marchetti B; Desole MS; Miele E; Serra PA
J Pineal Res; 2006 Apr; 40(3):204-13. PubMed ID: 16499555
[TBL] [Abstract][Full Text] [Related]
19. Partial damage to nigrostriatal bundle: compensatory changes and the action of L-dopa.
Zigmond MJ; Abercrombie ED; Stricker EM
J Neural Transm Suppl; 1990; 29():217-32. PubMed ID: 2193107
[TBL] [Abstract][Full Text] [Related]
20. The site of dopamine formation in rat striatum after L-dopa administration.
Hefti F; Melamed E; Wurtman RJ
J Pharmacol Exp Ther; 1981 Apr; 217(1):189-97. PubMed ID: 7205652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
